ArticleBMJ open diabetes research & care2026
Feasibility and cost-effectiveness of at-home self-sampling screening for type 2 diabetes: a pilot screening study in Denmark.
Article in BMJ open diabetes research & care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differences in screen-detected type 2 diabetes in two targeted community-based screening campaigns in Denmark.BMJ open diabetes research & care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe increased use of HbA1c as a diagnostic criterion, novel methods to collect and store blood samples as well as the quality of national registers enable screening targeted individuals, who are not screened opportunistically. The study evaluates whether screening for type 2 diabetes using at-home self-sampling HbA1c tests, targeted people who have not had their HbA1c measured the last 2 years, is feasible and cost-effective. RESEARCH DESIGN AND
methodsDuring a period of 9 months, the Danish Diabetes Association mailed free capillary at-home self-sampling HbA1c tests to 8,000 randomly selected individuals aged 50-75 years who had not had their HbA1c measured in the past 2 years. The screening costs per screen-detected derived from the pilot study and estimated cost savings across HbA1c levels derived from a Danish simulation study was used to estimate cost-effectiveness.
resultsAbout 38% returned a blood sample. The share of participants with HbA1c of 48 mmol/mol (6.5%) and above was 1.7% (50/2913). The screening costs were 1.207 per screen-detected with type 2 diabetes. A national screening program targeting individuals aged 50 to 75 years, who have not had their HbA1c measured within the previous 2 years, is estimated to reduce healthcare costs and productivity losses by €1514 per screen-detected, if diagnosis is moved forward by 3 years, as derived from a Danish simulation study. Hence, the total social return ratio of the screening program is estimated to €1514/ €1183=1.28.
conclusionsThe study suggests that screening for type 2 diabetes using at-home self-sampling HbA1c tests, targeting individuals aged 50-75, who have not had their HbA1c measured the past 2 years, is feasible and cost-effective in Denmark.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.